Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess Efficacy and Safety of LB03002 Administered Weekly in Adults With Growth Hormone Deficiency.

NCT00294619 is registered in ClinicalTrials.gov with LG Life Sciences as lead sponsor.

NCT NCT00294619
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00294619 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess Efficacy and Safety of LB03002 Administered Weekly in Adults With Growth Hormone Deficiency.
Lead sponsor
LG Life Sciences
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2006
Completion date
March 31, 2008
Enrollment
147 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adult growth hormone deficiency, pituitary disorders